Analyst Price Targets — BMY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 6, 2026 12:44 pm | Michael Yee | UBS | $70.00 | $59.79 | StreetInsider | Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst |
| February 24, 2026 9:03 pm | Trung Huynh | RBC Capital | $60.00 | $61.60 | StreetInsider | RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform |
| February 23, 2026 11:32 am | — | Piper Sandler | $75.00 | $60.66 | TheFly | Bristol Myers price target raised to $75 from $66 at Piper Sandler |
| February 19, 2026 9:15 pm | — | Barclays | $75.00 | $60.30 | TheFly | Bristol Myers initiated with an Overweight at Barclays |
| February 6, 2026 3:41 pm | Terence Flynn | Morgan Stanley | $40.00 | $61.86 | TheFly | Bristol Myers price target raised to $40 from $37 at Morgan Stanley |
| February 6, 2026 12:22 pm | — | Guggenheim | $72.00 | $59.52 | TheFly | Bristol Myers price target raised to $72 from $62 at Guggenheim |
| February 6, 2026 11:21 am | Mohit Bansal | Wells Fargo | $60.00 | $59.52 | TheFly | Bristol Myers price target raised to $60 from $55 at Wells Fargo |
| January 28, 2026 11:42 am | — | Piper Sandler | $66.00 | $55.56 | TheFly | Bristol Myers price target raised to $66 from $62 at Piper Sandler |
| January 13, 2026 2:13 pm | David Risinger | Leerink Partners | $60.00 | $56.39 | TheFly | Bristol Myers price target raised to $60 from $54 at Leerink |
| January 9, 2026 3:30 pm | Louise Chen | Scotiabank | $60.00 | $55.87 | TheFly | Bristol Myers price target raised to $60 from $53 at Scotiabank |
Latest News for BMY
In the latest trading session, Bristol Myers Squibb (BMY) closed at $60.74, marking a -2.55% move from the previous day.
Bristol Myers Squibb can navigate the dreaded patent cliff while maintaining modest dividend growth. Medtronic's strong, innovative business helps support its impressive dividend program.
Reblozyl tops $2.3B in annualized sales, emerging as a key drug for Bristol Myers as demand rises in MDS-related anemia and new study data support expansion.
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation (P/E 26.41 vs. 5-year 34.81x), and robust earnings growth, making it a core hold. Bristol Myers Squibb and AbbVie are both considered holds due to disappointing or modest dividend raises and valuations above historical…
111 Capital acquired a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 20,038 shares of the biopharmaceutical company's stock, valued at approximately $904,000. Several other institutional investors
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.